上海仁度生物科技股份有限公司2025年度业绩快报公告

Financial Performance Summary - In the fiscal year 2025, the company reported operating revenue of 162.06 million RMB, a decrease of 8.62% year-on-year [4] - The net profit attributable to the parent company was 9.51 million RMB, an increase of 17.32 million RMB compared to the previous year [4] - The net profit attributable to the parent company after deducting non-recurring gains and losses was -12.28 million RMB, an increase of 7.28 million RMB year-on-year [4] - Total assets at the end of the reporting period were 989.51 million RMB, a decrease of 0.49% from the beginning of the period [4] - Equity attributable to the parent company was 913.33 million RMB, an increase of 0.16% from the beginning of the period [4] Factors Influencing Performance - The company implemented a "quality improvement and efficiency enhancement" action plan, focusing on cost reduction and expense control, which led to a year-on-year decrease in period expenses [5] - Enhanced management of receivables allowed the company to recover some receivables from previous years, resulting in the reversal of some impairment losses according to accounting standards [5] Significant Changes in Financial Metrics - The operating profit, total profit, net profit attributable to the parent company, and net profit after deducting non-recurring gains and losses increased by 24.33 million RMB, 24.76 million RMB, 17.32 million RMB, and 7.28 million RMB respectively compared to the previous year, primarily due to the factors mentioned above [6]